{
    "clinical_study": {
        "@rank": "41689", 
        "arm_group": [
            {
                "arm_group_label": "40-50 years old", 
                "arm_group_type": "Experimental", 
                "description": "GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old"
            }, 
            {
                "arm_group_label": "65-74 years old", 
                "arm_group_type": "Experimental", 
                "description": "GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old"
            }, 
            {
                "arm_group_label": "75 years and older", 
                "arm_group_type": "Experimental", 
                "description": "GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the amount of compound present in the blood\n      (pharmacokinetics) after single and of multiple doses of GLPG0634 in elderly healthy\n      subjects.\n\n      During the course of the study, the effect of aging on the pharmacokinetics as well as the\n      effects of GLPG0634 on mechanism of action-related parameters in the blood\n      (pharmacodynamics) will be assessed and the safety of multiple oral doses of GLPG0634 in\n      elderly healthy subjects will be characterized."
        }, 
        "brief_title": "Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female, age 40 years and older\n\n          -  BMI between 18-30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any condition that might interfere with the procedures or tests in this study\n\n          -  Drug or alcohol abuse\n\n          -  Smoking"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665924", 
            "org_study_id": "GLPG0634-CL-104"
        }, 
        "intervention": {
            "arm_group_label": [
                "40-50 years old", 
                "65-74 years old", 
                "75 years and older"
            ], 
            "intervention_name": "GLPG0634 100mg capsule once a day for 10 days", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium", 
                    "zip": "2060"
                }, 
                "name": "SGS LSS Clinical Pharmacology Unit Antwerp"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects", 
        "overall_official": [
            {
                "affiliation": "Galapagos NV", 
                "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "SGS LSS Clinical Pharmacology Unit Antwerp", 
                "last_name": "Magdalena Petkova, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To characterize the amount of GLPG0634 in plasma over time - pharmacokinetics (PK) - after single and multiple oral doses in different age groups, including elderly healthy subjects, thereby assessing the effect of aging", 
            "measure": "The amount of GLPG0634 in plasma over time after single and multiple doses of GLPG0634", 
            "safety_issue": "No", 
            "time_frame": "From predose (before first study drug administration) up to 72 hours post last study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665924"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the effects of GLPG0634 on mechanism of action-related biomarkers in the blood over time - pharmacodynamics (PD) - after multiple oral doses in different age groups, including elderly healthy subjects, thereby assessing the effect of aging", 
                "measure": "The amount of GLPG0634 mechanism-of-action-related biomarkers in blood after multiple doses of GLPG0634", 
                "safety_issue": "No", 
                "time_frame": "From predose (before first study drug administration) up to 24 hours post last study drug administration"
            }, 
            {
                "description": "To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of the number of adverse events reported", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after the last study drug administration"
            }, 
            {
                "description": "To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in vital signs as measured by heart rate, blood pressure and body temperature reported", 
                "measure": "Changes in vital signs as measured by heart rate, blood pressure and body temperature", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after the last study drug administration"
            }, 
            {
                "description": "To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in 12-ECG measures reported", 
                "measure": "Changes in 12-lead ECG measures", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after the last study drug administration"
            }, 
            {
                "description": "To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in physical examination reported", 
                "measure": "Changes in physical exam measures", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after the last study drug administration"
            }, 
            {
                "description": "To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in blood safety lab parameters assessed", 
                "measure": "Changes in blood safety lab parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after the last study drug administration"
            }, 
            {
                "description": "To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in urine safety lab parameters assessed", 
                "measure": "Changes in urine safety lab parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after the last study drug administration"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}